(Q42051427)

15 October 2017

1 reference

title

Adjuvant system AS01: helping to overcome the challenges of modern vaccines (English)

1 reference

15 October 2017

5

Catherine Collignon

1 reference

15 October 2017

Arnaud M Didierlaurent

1

1 reference

15 October 2017

Béatrice Laupèze

2

1 reference

15 October 2017

Alberta Di Pasquale

3

1 reference

15 October 2017

Nadia Hergli

4

1 reference

15 October 2017

Nathalie Garçon

6

1 reference

15 October 2017

22 July 2016

1 reference

Expert Review of Vaccines

15 October 2017

1 reference

15 October 2017

16

1 reference

15 October 2017

1

1 reference

15 October 2017

55-63

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

15 October 2017

start time

2 August 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Towards an understanding of the adjuvant action of aluminium

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Vaccine adjuvants: current challenges and future approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Key roles of adjuvants in modern vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Mechanisms of action of adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Systematic review of incidence and complications of herpes zoster: towards a global perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Immune senescence and vaccines to prevent herpes zoster in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Humoral and cellular immunity to varicella-zoster virus: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Use of defined TLR ligands as adjuvants within human vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

The mechanism of action of MF59 - an innately attractive adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Vaccine Adjuvants: from 1920 to 2015 and Beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

T cell responses to the RTS,S/AS01e and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Safety and efficacy of the RTS, S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1213632

10.1080/14760584.2016.1213632

21 January 2018

Identifiers

DOI

1 reference

15 October 2017

1 reference